FGFR

ADC Related

ADC Antibody ADC Cytotoxin ADC Linker ADCs Drug-Linker Conjugates for ADC
Angiogenesis

5-alpha Reductase ALK Bcr-Abl BTK EGFR FAK FLT3 HER-2 HIF Src Syk VDA VEGFR
Anti-infection

Antibiotic Arenavirus Bacterial CMV EBV Enterovirus Filovirus Fungal Gli HBV HCV HCV Protease HIV HSV Influenza Virus Parasite RABV Reverse Transcriptase RSV SARS-CoV TMV Virus Protease
Apoptosis

Apoptosis ASK Bcl-2 Caspase c-Myc c-RET Cytohesin DAPK Ferroptosis FKBP IAP Mdm2 p53 PD-1 PD-L1 PERK PKD Ras RIP kinase ROS Survivin Thymidylate Synthase TNF Receptor TNFa TRADD
Autophagy

Autophagy LRRK2 Mitophagy OGA ULK
Cell Cycle

Antifolate APC Aurora Kinase BMI-1 CDK Chk c-Myc Eukaryotic Initiation Factor G-quadruplex HDAC HSP Kinesin LIMK Mad2 Microtubule(Tubulin) Mps1 Nucleoside Antimetabolite/Analog Nur77 p21 PAK PERK PFKFB PLK PPAR Ras Rho ROCK SRPK TOPK Topoisomerase Wee1
Cytoskeletal Signaling

Arp2 3 Complex Bcr-Abl Cardiac Myosin Dynamin Gap Junction Protein HSP Integrin Kinesin Microtubule Associated MLCK Myosin PAK TACC3 Wntbeta-catenin
DNA Damage

ATM(ATR) CRISPR(Cas9) DNA alkylator DNA Stain DNA(RNA) Synthesis GAK HDAC HSP Nucleoside Antimetabolite(Analog) OGG1 p97 PARG PARP RAD51 RNR Sirtuin SMN Telomerase Topoisomerase
Endocrinology & Hormones

5-alpha Reductase ACE Adrenergic Receptor Androgen Receptor Aromatase Estrogenprogestogen Receptor Glucocorticoid Receptor GPR Mineralocorticoid Receptor RAAS THR TSH Receptor
Epigenetics

AMPK Aurora Kinase DNA Methyltransferase Epigenetic Reader Domain EZH1 2 HDAC HIF Histone Acetyltransferase Histone Demethylase Histone Methyltransferase JAK MAT MicroRNA MLL Pim PKC Protein Arginine Deiminase Sirtuin Small Interfering RNA (siRNA) SMYD

+MORE

FGFR

FGFR (Fibroblast growth factor receptors) are the receptors that bind to members of the fibroblast growth factor family of proteins.Pathological conditions involve some of these receptors. Achondroplasia can be brought on by a point mutation in FGFR3. Vertebrates have been found to contain five distinct membrane FGFRs, all of which are members of the tyrosine kinase superfamily (FGFR1, FGFR2, FGFR3, FGFR4, FGFR6). One of the most significant families of paracrine factors that function in the development process is the fibroblast growth factor family. They control which cells differentiate into mesoderm, the production of blood vessels, the growth of limbs, and the growth and differentiation of many different cell types.

FGFR related products

Cat No.	Product Name	CAS No.	Product Description
V3276	ACTB-1003	939805-30-8	ACTB-1003 is an orally available multi-kinase inhibitorwithIC50values of 6, 2 and 4 nM forFGFR1,VEGFR2andTie-2.
V88041	Antitumor agent-176		Antitumor agent-176 (Compound 22) is an antitumor agent that potently binds to FGF2 and inhibits fibroblast growth factor receptor (FGFR) activation in multiple myeloma (MM) cells, with significant in vivo effects on MM and in vitro antitumor activity.
V88043	Antitumor agent-177		Antitumor agent-177 (compound 57) is a nonsteroidal NSC12 derivative that displays potent FGF2 binding affinity with a Kd of 24 μM as measured by SPR.
V5222	ASP-5878	1453208-66-6	ASP5878 is a novel, potent,selective and orally bioactive inhibitor of FGFR 1, 2, 3, and 4, with IC50values of 0.47 nM, 0.6 nM, 0.74 nM and 3.5 nM for FGFR 1, 2, 3, and 4 kinase activity.
V87107	B-Raf IN 17		B-Raf IN 17 (Compound 8e) is a potent and orally active type II multikinase inhibitor.
V2693	BLU-554(BLU-554)	1707289-21-1	BLU-554 is a novel potent, highly-selective, and orally bioavailable inhibitor of FGFR4 (fibroblast growth factor receptor 4) with an IC50 value of 5 nM in cell free assays.
V0617	BLU9931	1538604-68-0	BLU9931 (BLU-9931; BLU 9931) is an irreversible and selective FGFR4 inhibitor with potential anticancer activity.
V37655	BO-264	2408648-20-2	BO-264 is a novel and orally bioactive transforming acidic coiled-coil 3 (TACC3) inhibitor with an IC50 of 188 nM and a Kd of 1.5 nM.
V88031	BR-cpd7		BR-cpd7 is a PROTAC degrader of fibroblast growth factor receptor (FGFR1/2) with a DC50 of 10 nM.
V86160	CEP-11981 tosylate (ESK981 tosylate; BOL 303213X tosylate)	901128-79-8
V69468	CPL304110	1627826-19-0	CPL304110 is a potent, orally bioavailable, and selective inhibitor of the fibroblast growth factor receptor FGFR (1-3) with IC50s of 0.75 nM, 0.5 nM, and 3.05 nM for FGFR (1-3).
V88040	CXF-007	2727083-99-8	CXF-007 is a potent and specific FGFR4 inhibitor with an IC50 value of 7 nM.
V88039	CXF-009	2727084-00-4	CXF-009 is a selective, covalent FGFR4 inhibitor with an IC50 value of 48 nM.
V84741	CYY292	2644673-04-9
V69485	Efruxifermin	2375240-92-7	Efruxifermin is an Fc-FGF21 fusion protein (human IgG1 Fc domain linked to modified human FGF21).
V0616	Fexagratinib (AZD-4547; ADSK-091)	1035270-39-3	AZD4547 (AZD-4547; AZD 4547) is a novel and orally bioavailable FGFR (fibroblast growth factor receptor) inhibitor with potential antineoplastic activity.
V69458	FGFR-IN-1	1513860-41-7	FGFR-IN-1 is a potent FGFR inhibitor (antagonist) with IC50 of less than 100 nM for FGFR1, FGFR2 and FGFR3 respectively.
V69466	FGFR-IN-11	2658488-68-5	FGFR-IN-11 (compound I-5) is an orally bioactive and covalent pan-FGFR inhibitor (antagonist) with IC50s of 9.9 nM (FGFR1), 3.1 nM (FGFR2), 16 nM (FGFR3) and 1.8 respectively.
V69464	FGFR-IN-12	943189-02-4	FGFR-IN-12 (example 14) is a pyrimidinyl aryl urean analogue and a potent FGFR inhibitor.
V88036	FGFR-IN-13	2962941-25-7	FGFR-IN-13 (compound III-30) regulates signaling pathways mediated by endogenous FGFR1 (IC50=0.20±0.02 nM) and FGFR4 (IC50=0.40±0.03 nM) by inhibiting the expression of key proteins.